Alerts
Cataplexy Is Waiting on an FDA Clock
FDA has accepted Axsome’s NDA for AXS-12 in cataplexy associated with narcolepsy. The review is now formal, but approval, access and specialist recognition are still unresolved.
An ADC Steps Into the First-Line Gap in Triple-Negative Breast Cancer
Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test
Ebola PHEIC Turns Outbreak Control Into a Preparedness Test
Huntington’s Disease Gets an Oral Target-Engagement Signal
A New CELMoD Raises the Bar in Relapsed Myeloma
IPM Alliance launches at the World Health Assembly in Geneva
Regulators Start Writing the Rules for AI-Driven Medicines
FDA Puts AI Inside the Evidence Machine
AI Diagnosis Has Entered the Access Debate
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.